Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-02-11 22:30 |
Monthly information on share capital and company voting rights
|
English | 87.7 KB | ||
| 2022-02-10 22:30 |
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer
|
English | 76.6 KB | ||
| 2022-02-10 22:30 |
Cellectis nomme Bing Wang, PhD, MBA, en tant que directeur financier
|
French | 65.5 KB | ||
| 2022-01-10 22:30 |
Cellectis annonce la levée de l’avis de suspension par la FDA des essais cliniq…
|
French | 83.5 KB | ||
| 2022-01-10 22:30 |
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Cl…
|
English | 121.0 KB | ||
| 2022-01-04 22:30 |
Cellectis dévoile ses objectifs business pour l’année 2022 et sa nouvelle prése…
|
French | 100.8 KB | ||
| 2022-01-04 22:30 |
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Prese…
|
English | 118.3 KB | ||
| 2021-12-11 16:07 |
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Ref…
|
English | 140.9 KB | ||
| 2021-12-06 22:30 |
Monthly information on share capital and company voting rights
|
English | 32.0 KB | ||
| 2021-12-06 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 32.0 KB | ||
| 2021-11-18 22:30 |
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable…
|
English | 109.8 KB | ||
| 2021-11-18 22:30 |
Cellectis et Cytovia étendent leur partenariat en Chine pour développer des cel…
|
French | 114.0 KB | ||
| 2021-11-12 14:10 |
Society for Immunotherapy of Cancer (SITC) : Cellectis présente les premières d…
|
French | 58.2 KB | ||
| 2021-11-12 14:09 |
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cel…
|
English | 87.5 KB | ||
| 2021-11-08 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 88.9 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
